OTCMKTS:RHHBY

Roche Holding Ag Stock News

Healthcare > Drug Manufacturers - General

Buy RHHBY

*Your capital is at risk

$54.64

-0.630 (-1.14%)

At Close: Jul 31, 2026

Roche's Breast Cancer Drug Cuts Risk of Death by 30% in Phase III

11:31am, Thursday, 11'th Dec 2025

RHHBY's giredestrant cuts the risk of invasive disease recurrence or death by 30% in phase III, fueling momentum for a next-generation endocrine therapy.

Roche expands automated mass spectrometry menu with antibiotics drug monitoring CE mark approval offering industry's broadest in vitro diagnostic menu

01:00am, Thursday, 11'th Dec 2025

Basel, 11 December 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has secured CE Mark approval for its mass spectrometry reagent pack for antibiotics drug monitoring. This establish

Market Today: Fed Cut; Oracle, Rivian, Amazon in Focus

05:34pm, Wednesday, 10'th Dec 2025

Guru Stock PicksPaul Tudor Jones has made the following transactions:Reduce in DOMO by 74.59%Sold out in ITAdd in BRY by 6686.5%New position in LDOSStock News F

Questex's Patients as Partners® in Clinical Research Unveils Conference Program, Thought Leaders from Lurie Children's Hospital, Roche Canada and Tufts University School of Medicine to Keynote

10:05am, Wednesday, 10'th Dec 2025

Patients as Partners® in Clinical Research Now Part of Questex's Fierce Life Sciences Portfolio; First Conference to Put Patients at the Same Level as R&D Executives in a National Event Takes Place i

Roche Says Breast-Cancer Drug Shows Potential to Become Standard-Of-Care

09:20am, Wednesday, 10'th Dec 2025

Giredestrant lowered the risk of disease recurrence or death by 30%, compared with standard-of-care endocrine therapy, according to the company.

Genentech's Giredestrant Reduced Risk of Invasive Disease Recurrence or Death by 30% in ER-positive Early-Stage Breast Cancer

08:20am, Wednesday, 10'th Dec 2025

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive data from the Phase III lidERA Breast Cancer study evaluatin

Roche breast cancer pill cuts risk of disease recurrence by 30% in trial

08:16am, Wednesday, 10'th Dec 2025

Roche said on Wednesday its experimental oral drug giredestrant reduced the risk of breast cancer recurrence by 30% compared with standard endocrine therapy, in what it said marked the first big advan

Roche's giredestrant reduced risk of invasive disease recurrence or death by 30% in ER-positive early-stage breast cancer

08:15am, Wednesday, 10'th Dec 2025

Basel, 10 December 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive data from the phase III lidERA Breast Cancer study evaluating investigational giredestrant as an adjuvant endocrin

First Look: Fed Cut Looms; SpaceX IPO; J&J Myeloma Data; Google Probe

07:37am, Wednesday, 10'th Dec 2025

Stock News Fed set for a âhawkish cutâ: The Federal Reserve is widely expected to deliver a third 25 bp rate cut amid sharp divisions over inflation vs. job

Market Today: Fed Cut Looms, Nvidia's China Shift, Target's SoHo Push, OpenAI Taps Slack CEO

05:34pm, Tuesday, 09'th Dec 2025

Stock News Fed set for âhawkish cut': Goldman Sachs (GS) and other Wall Street desks expect the Federal Reserve to deliver a third straight 25 bps rate cut wh

First Look: Paramount's WBD bid, IBM-Confluent, Boeing-Spirit

07:37am, Tuesday, 09'th Dec 2025

Stock News Paramount goes hostile for WBD: Paramount Skydance (PSKY) launched a hostile, all-cash $30-per-share offer for Warner Bros. Discovery (WBD), valuing

Roche launches new PCR test to help improve diagnostic accuracy for women affected by vaginitis in countries following the CE Mark

01:10am, Tuesday, 09'th Dec 2025

Basel, 9 December 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the CE Mark for its cobas® BV/CV (Bacterial Vaginosis/Candida Vaginitis) assay to accurately identify specific bacteria and

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by